[Frontiers in Bioscience 3, a11-15, February 1, 1998]
Reprints
PubMed
CAVEAT LECTOR




Table of Conents
 Previous Section   Next Section

TARGETED INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION: A GENE THERAPY APPROACH

Frank Y.-T. Tung and Steven W. Bowen

Department of Infectious Disease and Microbiology, University of Pittsburgh, Pittsburgh PA 15261

Received 1/21/98 Accepted 1/28/98

7. REFERENCES

1. F.B. Hollinger: Hepatitis B virus. In Fields virology. Eds: Fields B.N., and Knipe D.M., Raven Press, New York, NY (1990)

2. Ganem, D: Persistent infection of humans with hepatitis B virus: mechanisms and consequences. Rev. Infect. Dis. 4,1026-1027 (1979)

3. J.M. Hoofragle, and H. Alter: Chronic viral hepatitis. In Viral Hepatitis and Liver Disease. Eds:Vyas, G.N., Dienstag J.L., and Houfragle J., Grune S. Stratton, Orlando, FL (1984)

4. Beasley, R.P., C.-C. Liu, L.-Y. Hwang, and C.-S. Chien: Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22, 707 men in Taiwan. Lancet 2,1129-1133 (1981)

5. Summers, J., and W.S. Mason: Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29,403-415 (1982)

6. Shih, C., K. Burke, M.J. Chou, J.B. Zeldis, C.S. Yang, C.S. Lee, K.J. Isselbacher, J.R. Wands, and H.M. Goodman:Tight clustering of human hepatitis B virus integration sites in hepatomas near a triple-stranded region. J. Virol. 61,3491-3498 (1987)

7. Yaginuma, K., H. Kobayashi, M. Morishima, K. Matsuyama, and K. Koike: Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J. Virol. 61,1808-1813(1987)

8. Francis, D.P., M. Essex, and J.E. Maynard: Feline leukemia virus and hepatitis B virus: a comparison of late manifestations. Prog. Med. Virol. 27:127-132 (1981)

9. Francis, D.P., and J.E. Maynard:The transmission and outcome of hepatitis A, B, and non-A, non-B: a review. Epidemiol Rev. 1,17-31 (1979)

10. DeGroote, J., J. Fevery, L. Lepouter: Long-term follow-up of chronic active hepatitis of moderate severity. Gut 19, 510-513 (1978)

11. Bianchi, L., and F. Gudat: Immunopathology of hepatitis B. Prog. Liver Dis. 6:371-392 (1979)

12. F. Chisari, J. Routenberg and D. Anderson: Cellular immune reactivity in HBV induced liver diesease. In Viral Hepatitis. Eds: G. Vyas, S. Cohen, and R. Schmid, Franklin Inst., Philadelphia, PA (1978)

13. J.L. Dienstag: Immunological mechanisms in chronic viral hepatitis. In Viral Hepatitis and Liver Disease. Eds: Vyas, G.N., J.L. Dienstag and J. Houfragle, Grune S. Stratton, Orlando, FL (1984)

14. Dudley, F., R. Fox, S. Sherlock: Cellular immunity and hepatitis-associated, Australia antigen liverdisease. Lancet 1,763-766 (1972)

15. Wong, D.K., A.M.Cheung, K. O’Rourke, C.D. Naylor, A.S. Detsky, J. Heathcote: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 119,312-323 (1993)

16. Colgrove, R., G. Simon, and D. Ganem:Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J. Virol. 63, 4019-4026 (1989)

17. Siddigui, A.R., R. Gayner, A. Srinivasan, J. Mapoles, and R.W. Far:Trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 169, 479-484 (1989)

18. Zahm, P., P.H. Hofschneider, and R. Koshy: The HBV X-ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis. Oncogene 3,169-177 (1988)

19. Dal Monte P., C.Bessia, A. Ripalti, M.P.Landini, A. Topilko, B. Plachter, J.L.Virelizier, S. Michelson: Stably expressed antisense RNA to cytomegalovirus UL83 inhibits viral replication. J. of Virology 70, 2086-2094 (1996)

20. Tung, F.Y.T., and M.D. Daniel:Targeted inhibition of immunodeficiency virus replication in lymphocytes through retroviral mediated gene transfer. Archives of Virology 133,407-421 (1993)

21. Whitton, J.L. Antisense treatment of viral infection. Advances in Virus Research 44,267-303 (1994)

22. Goodarzi G.,S.C. Gross, A. Tewari, and K. Watabe: Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J. Gen. Virol. 71:3021-3025 (1990)

23. Offensperger, W. B., H. E. Blum, and W. Gerok: Molecular therapeutic strategies in hepatitis B virus infection. Clin Investig 72:737-741 (1994)

24. Offensperger W., S. Offensperger, E.Walter, K. Teubner, G. Igloi, H. Blum, and W. Gerok:In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. The EMBO 12:1257-1262 (1993)

25. Ledley, F.D., G.J. Darlington, T. Hahn, and S.L.C.Woo :Retroviral gene transfer into primary hepatocytes: Implications for genetic therapy of live-specific functions. Proc. Natl. Acad. Sci. USA 84,5335-5339 (1987)

26. Miller, D.A. and G.J. Rosman:Improved Retroviral Vectors for Gene Transfer and Expression. Biotechniques. 7,980-989 (1989)

27. Penna A., P. Fowler, A. Bertoletti, S.Guilhot, B. Moss, R.F. Margolskee, A. Cavalli, A.Valli, F. Fiaccadori, F.V. Chisari:Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens. J. of Virology 66,1193-8 (1992)

28. Barnaba V., A. Franco, A. Alberti, C. Balsano, R. Benvenuto, F. Balsano:Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J. of Immunology 143,2650-5 (1989)

29. Lo S.J., Y.H. Lee, J.S. Chiou, L.P. Ting, W.T. Liu, KB. Choo: Characterization of restriction endonuclease maps of hepatitis B viral DNAs. Bioch.& Bioph. Res. Comm. 129,797-803 (1985)

30. Guedez, L., A. Suresh, F.Y.T. Tung, and J. Zucali: Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Euro. J. Hematology 57,149-56 (1996)

31. Markowitz, D., S. Goff, and A. Bank: A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1120-1124 (1988)

32. Christman J. K., M. Gerber, P.M. Price, C. Flordellis, J. Edelman, and G. Acs: Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA. Proc. Natl. Acad. Sci. USA 79,1815-1819 (1982)

33. Carman W., H. Thomas, and E. Dominco: Viral genetic variation: hepatitis B virus as a clinical example. The Lancet 341:349-353 (1993)

34. Welch, P.J. , R. Tritz, S. Yei, J. Barber, and M.Yu: Intracellular application of hairpin ribozyme gene against hepatitis B virus. Gene therapy 4, 736-743 (1997)